96-98-0 Usage
Description
4-Methyl-3-nitrobenzoic acid is a white to light yellow crystalline powder, also known as prismatic crystals or off-white powder. It is an organic compound with the chemical formula C8H7NO4.
Uses
Used in Pharmaceutical Industry:
4-Methyl-3-nitrobenzoic acid is used as an intermediate in the synthesis of pharmaceuticals for its versatile chemical properties.
Used in Synthesis of Lanthanide Coordination Complexes:
4-Methyl-3-nitrobenzoic acid is used as a ligand in the synthesis of one-dimensional (1D) lanthanide coordination complexes, which have potential applications in various fields such as luminescent materials, magnetic materials, and catalysis.
Air & Water Reactions
Insoluble in water.
Reactivity Profile
4-Methyl-3-nitrobenzoic acid is a nitrated carboxylic acid. Carboxylic acids donate hydrogen ions if a base is present to accept them. They react in this way with all bases, both organic (for example, the amines) and inorganic. Their reactions with bases, called "neutralizations", are accompanied by the evolution of substantial amounts of heat. Neutralization between an acid and a base produces water plus a salt. Carboxylic acids with six or fewer carbon atoms are freely or moderately soluble in water; those with more than six carbons are slightly soluble in water. Soluble carboxylic acid dissociate to an extent in water to yield hydrogen ions. The pH of solutions of carboxylic acids is therefore less than 7.0. Many insoluble carboxylic acids react rapidly with aqueous solutions containing a chemical base and dissolve as the neutralization generates a soluble salt. Carboxylic acids in aqueous solution and liquid or molten carboxylic acids can react with active metals to form gaseous hydrogen and a metal salt. Such reactions occur in principle for solid carboxylic acids as well, but are slow if the solid acid remains dry.
Fire Hazard
Information concerning the flash point of 4-Methyl-3-nitrobenzoic acid is not available. 4-Methyl-3-nitrobenzoic acid is probably combustible.
Purification Methods
Recrystallise the acid from EtOH. The S-benzylisothiuronium salt has m 167168o (EtOH). The acid chloride [10397-30-5] has m 20-21o, b 185o/36mm, and the methyl ester [7356-11-8] crystallises as pale yellow needles from MeOH with m 51o. [Beilstein 9 H 502, 9 II 334, 9 III 2359.]
Check Digit Verification of cas no
The CAS Registry Mumber 96-98-0 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 9 and 6 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 96-98:
(4*9)+(3*6)+(2*9)+(1*8)=80
80 % 10 = 0
So 96-98-0 is a valid CAS Registry Number.
InChI:InChI=1/C8H7NO4/c1-5-2-3-6(8(10)11)4-7(5)9(12)13/h2-4H,1H3,(H,10,11)/p-1
96-98-0Relevant articles and documents
-
Ospenson
, p. 710 (1950)
-
Facile Synthesis of N-(Benzyl-1H-1,2,3-Triazol-5-yl) Methyl)-4-(6-Methoxybenzo [d] Thiazol-2-yl)-2-Nitrobenzamides via Click Chemistry
Yarlagadda, Bharath,Devunuri, Nagaraj,Mandava, V. Basaveswara Rao
, p. 864 - 870 (2017/03/27)
A series of novel N-((l-benzyl-lH-l,2,3-triazol-5-yl) methyl)-4-(6-methoxy benzo[d]thiazol-2-yl)-2-nitrobenzamide derivatives were prepared from 4-(6-methoxybenzo[d]thiazol-2-yl)-2-nitro-N-(prop-2-ynyl) benzamide with benzyl azides by using click reaction (copper-catalyzed Huisgen 1,3-dipolar cycloaddition reaction) in the presence of CuSO4.5H2O and sodium ascaorbate. All the newly synthesized compounds were evaluated further in vitro antimicrobial activity against Gram-positive bacteria (Staphylococcus aureus and Bacillus subtillis), Gram-negative bacteria (Echerichia coli and Pseudomonas aeuroginosa), and fungi (Aspergillus niger and Aspergillusfumigatus) strains. The new compounds were characterized based on spectroscopic evidence. Among them compounds 10a, 10h, and 10i were showed promising activity when compared with standard drugs Ciprofloxacin and Miconazole.
Substituted Spiroamide Compounds
-
Page/Page column 20, (2010/09/18)
Substituted spiroamide compounds corresponding to formula (I): wherein A, B, Q1, Q2, Q3, Q4, R1, R8, R9a, R9b, R12, R13, R200 and R210 have defined meanings, processes for their preparation, pharmaceutical compositions containing such compounds, and the use of such compounds for treating or inhibiting pain or other conditions mediated at least in part by the bradykinin 1 receptor (B1R).